Peripheral Arterial Disease Trial, Recruiting NCT04393389 Sponsor: Acotec Scientific Co., Ltd Condition: Peripheral Arterial Disease
Back to Peripheral Arterial Disease

Peripheral Arterial Disease Trial, Recruiting

NCT04393389
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older at the time of giving consent.
  • People who have a significant narrowing (70% or more) or blockage in one or more arteries in the hip, thigh, knee, or lower leg area, in either a new or previously treated area, that a doctor determines is suitable for a balloon procedure.
  • People whose artery narrowing or blockage can be treated using one of the specific balloon devices used in this trial (AcoArt Orchid, AcoArt Tulip, or AcoArt Litos), according to the device instructions.
  • People who have given written consent before joining, understand the purpose of the study, and agree to attend all required check-ups and follow-up appointments.
  • People whose leg circulation problems fall within a specific severity range known as Rutherford Category 2 through 6 — with Category 2 applying only to those who have already tried non-surgical treatments without improvement.
  • People who have had any blockages further up the artery (closer to the heart) treated before the main procedure in this trial takes place.

Who may not be able to join:

  • People whose leg circulation problems fall into the mildest categories (Rutherford Category 0 or 1), meaning they have little to no symptoms.
  • People who are already enrolled in another research study that could affect the results of this trial.
  • People who are unable to take the required blood-thinning or anti-clotting medications.
  • People who have a severely hardened (calcified) blockage that cannot be opened with a balloon procedure.
  • People who have a known allergy or sensitivity to any part of the balloon device used in this trial.
  • People who have an untreated fresh or recent blood clot in the artery being treated.
  • People with a life expectancy of less than one year.
  • People who are pregnant, breastfeeding, or are of childbearing potential and are not using adequate contraception.
  • People with other serious health conditions that, in the treating doctor's opinion, may affect how long they live or whether they can reliably attend follow-up appointments.
  • People who have had a heart attack or stroke within the 30 days before the procedure.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Schmidt Andrej, Department of Angiology, University Hospital Leipzig

Phone: +49-341-97

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Acotec Scientific Co., Ltd
Registry
ClinicalTrials.gov
Start date
4 June 2020
Est. completion
1 December 2025

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Primary efficacy endpoint - non-CLI group; Primary efficacy endpoint -CLI group; Primary safety endpoint- non-CLI group; Primary safety endpoint- CLI group

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov